Celltrion targets $3.46 bn in sales this year on biosimilars
Seoul, March 18 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in sales this year, helped by an expanded biosimilar lineup. The annual target is 40.5 per cent higher than the record high of 3.56 trillion won it posted last year, Yonhap news […]
Celltrion launches autoimmune disease treatment in US
Seoul, March 13 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States. Celltrion launches autoimmune disease treatment in US Steqeyma, a treatment for plaque psoriasis, Crohn’s disease, active psoriatic arthritis and ulcerative colitis, is Celltrion’s seventh biosimilar […]
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment
Seoul, Jan 31 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The FDA approved Celltrion’s Avtozma, a biosimilar to Actemra, in both intravenous and subcutaneous formulations, according to the company, Yonhap news agency […]
